University of Kansas Cancer Center Post San Antonio Review
48 y/o PALB2 Mutation Carrier With T2N0 ER/PR+, HER2- BC: How to Counsel This Patient? What Treatment to Recommend in the Metastatic Setting?
Login to view comments.
Click here to Login
